BVXV - BiondVax Pharmaceuticals Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.55
-0.10 (-1.77%)
At close: 12:50PM EDT
Stock chart is not supported by your current browser
Previous Close5.65
Open5.55
Bid5.25 x 1000
Ask0.00 x 1100
Day's Range5.55 - 5.55
52 Week Range3.51 - 7.26
Volume2,100
Avg. Volume6,186
Market Cap36.319M
Beta (3Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial
    PR Newswire

    BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial

    JERUSALEM, Oct. 7, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine candidate, announced today the receipt of €4 million from the European Investment Bank (EIB). Dr. Ron Babecoff, BiondVax's President and CEO, commented, "This past June we were honored to welcome EIB Vice-President Mr. Ambroise Fayolle to our manufacturing facility in Jerusalem for a signature event celebrating the extension of the EIB-BiondVax financing agreement to €24 million.

  • BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results
    PR Newswire

    BiondVax Welcomes New Chairman of the Board and Announces Second Quarter 2019 Financial Results

    JERUSALEM , Aug. 28, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • Zacks Small Cap Research

    BVXV: Raises $20 Million; Phase 3 Trial Fully Funded…

    On July 16, 2019, BiondVax Pharmaceuticals Ltd. (BVXV) announced that the previously announced rights offering was fully subscribed and the company raised gross proceeds of $20 million through the sale of 3,057,466 American Depository Shares (ADSs) and 18,298,898 ordinary shares. BiondVax’s largest shareholder, Angels Investment High Tech Ltd. (which is wholly owned by Mr. Marius Nacht), fully subscribed for the entire allotment available to them and also exercised the option to purchase 2,203,640 ADSs and 141,538 ordinary shares that were not purchased by other shareholders. Thus, Angels Investment High Tech Ltd. total investment in the rights offering was $16.67 million, and the firm is now a controlling shareholder with a holding of approximately 42% of BiondVax.

  • BiondVax Announces Rights Offering Fully Subscribed at US$20 Million
    PR Newswire

    BiondVax Announces Rights Offering Fully Subscribed at US$20 Million

    JERUSALEM, Israel, July 16, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) is proud to announce today the results of its previously announced rights offering. The Company has received subscriptions from existing shareholders for all the offered American Depositary Shares ("ADSs") and ordinary shares, being a total of 3,057,466 ADSs and 18,298,898 ordinary shares, raising total gross proceeds of US$20 Million.

  • First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
    PR Newswire

    First Participant Enrolled in Second Cohort of BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial

    JERUSALEM, July 8, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled. Influenza viruses mutate frequently and unpredictably, and the strains that dominate often vary in time and place. For example, according to the CDC, the first part of the 2018/19 flu season was dominated by H1 strains throughout most of the continental USA, while the south-east USA was dominated by an H3 strain.

  • European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million
    PR Newswire

    European Investment Bank VP Attends Signature Event at BiondVax Extending Financing Agreement With BiondVax to €24million

    JERUSALEM, June 26, 2019 /PRNewswire/ -- The Board of Directors and Management of BiondVax Pharmaceuticals Ltd. (BVXV), was honored to host Mr. Ambroise Fayolle, Vice-President of the European Investment Bank (EIB), during his visit to BiondVax's new mid-size commercial scale manufacturing facility in Israel.

  • BiondVax Gets OK to Build Plant in Israel (BVXV)
    Investopedia

    BiondVax Gets OK to Build Plant in Israel (BVXV)

    BiondVax Pharmaceuticals Ltd. (BVXV) secured a grant from the Israel Investment Center, a unit of the Government of Israel's Ministry of Economy and Industry, to build a manufacturing facility for the production of Phase 3 and commercial batches of its universal flu vaccine, M-001. Influenza viruses often undergo changes to certain surface proteins which results in development of new virus strains that are unfamiliar to the human body immune system. The bigger the surface protein change, the lower the possibility of body’s immune system to fight against the disease.

  • Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan
    PR Newswire

    Patent Covering Manufacturing Process of BiondVax's M-001 Universal Flu Vaccine Allowed in USA and Japan

    JERUSALEM, June 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that a patent covering production processes of the Company's M-001 universal influenza vaccine candidate was allowed in the USA and Japan. Titled "Compositions of multimeric-multiepitope influenza polypeptides and their production" the patent, which is pending in Europe, covers the unique composition and manufacturing processes of M-001. Designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza, the vaccine has been shown to be safe, well-tolerated, and immunogenic to a broad range of flu strains in clinical trials.

  • Zacks Small Cap Research

    BVXV: Rights Offering to Finance Company Through Phase 3 Trial Results…

    With the company set to enter the second enrollment season for the ongoing Phase 3 clinical trial of its universal influenza vaccine M-001, a rights offering has recently been initiated in which the company is looking to raise approximately $20 million. The terms of the rights offering allow for each shareholder and American Depositary Share (ADS) holder to receive approximately 0.54 subscription rights for each 1 ADS or share owned. In exchange, Angels Investment asked that its affiliate, aMoon2 Fund Limited Partnership, be given the option to purchase any units offered but not purchased by other shareholders, but not less than $10 million combined between Angels Investment and aMoon2.

  • BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
    PR Newswire

    BiondVax Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process

    JERUSALEM, Israel, June 10, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced a rights offering to holders of the Company's American Depositary Shares ("ADSs"). Proceeds from the rights offering will be used to fund operations including completion of the ongoing pivotal, clinical efficacy Phase 3 trial of BiondVax's M-001 universal flu vaccine candidate, and scale up of the M-001 production process in BiondVax's newly constructed mid-size manufacturing facility.

  • BiondVax Announces First Quarter 2019 Financial Results
    PR Newswire

    BiondVax Announces First Quarter 2019 Financial Results

    JERUSALEM , May 30, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine ...

  • BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference
    PR Newswire

    BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at 18th MIXiii-BIOMED Conference

    JERUSALEM, Israel, May 13, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel. Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.

  • BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
    PR Newswire

    BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update

    JERUSALEM , April 30, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate currently ...

  • European Investment Bank (EIB) Extends Financing Agreement to €24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial
    PR Newswire

    European Investment Bank (EIB) Extends Financing Agreement to €24 Million Total in Support of BiondVax's Universal Flu Vaccine Ongoing Pivotal Phase 3 Clinical Trial

    JERUSALEM, April 22, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to extend the 2017 financing agreement with BiondVax by an additional €4 million. The funds will be used in support of the ongoing pivotal, clinical efficacy, Phase 3 trial of BiondVax's M-001 Universal Flu Vaccine candidate in Europe. The original €20 million EIB-BiondVax non-dilutive co-financing agreement was signed in June 2017 to support both construction of BiondVax's new mid-size commercial-scale manufacturing facility in Israel and the pivotal, clinical efficacy, Phase 3 trial in Europe.

  • Zacks Small Cap Research

    BVXV: Update on Phase 3 Clinical Trial of Universal Influenza Vaccine…

    BiondVax Pharmaceuticals Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial is being conducted in Europe following feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Universal Flu Vaccine Patent Application Accepted in Australia
    PR Newswire

    BiondVax Universal Flu Vaccine Patent Application Accepted in Australia

    JERUSALEM, April 15, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), announced today that a patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate was accepted in Australia. Titled "Compositions of multimeric-multiepitope influenza polypeptides and their production" the patent application has been filed in eight other jurisdictions, and is under examination in Europe, China, Japan, and the USA. Dr. Tamar Ben-Yedidia, BiondVax's Chief Science Officer, commented, "Our five patent families cover multimeric-multiepitope polypeptides as well as composition, use, formulation and production aspects of M-001, BiondVax's Phase 3 universal flu vaccine candidate.

  • BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference
    PR Newswire

    BiondVax to Provide Update of M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial at IVW2019 Conference

    JERUSALEM, March 28, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present next week at the Influenza Vaccines for the World conference in Edinburgh, Scotland, UK. Joshua Phillipson, BiondVax's Head of Business Development, will provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial.

  • Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate
    PR Newswire

    Last Participant out in USA Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate

    JERUSALEM, March 21, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today that all participants have completed their final visit in a Phase 2 clinical trial conducted by several Vaccine Treatment and Evaluation Units (VTEUs) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health & Human Services (HHS)'s National Institutes of Health (NIH). 120 participants aged 18 to 49 years were enrolled at VTEUs at Baylor College of Medicine in Houston, Texas, the University of Iowa in Iowa City, Iowa, and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. Individuals were randomly assigned to receive either two doses of M-001 or two doses of a placebo, with the doses spaced three weeks apart.

  • GlobeNewswire

    Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
    PR Newswire

    BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate

    JERUSALEM, Nov. 26, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego. Dr. Ron Babecoff, BiondVax's Founder and CEO, will participate in a panel discussion and provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial. Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?

  • Zacks Small Cap Research

    BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine…

    BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial is being conducted in Europe following feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).

  • BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
    PR Newswire

    BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results

    JERUSALEM , Nov. 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • BiondVax Announces Third Quarter 2018 Financial Results
    PR Newswire

    BiondVax Announces Third Quarter 2018 Financial Results

    JERUSALEM , Nov. 13, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...

  • BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
    PR Newswire

    BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants

    The 4,098 participants enrolled in this year's cohort will be monitored for two flu seasons. A second cohort of approximately 6,000 participants will be enrolled prior to the 2019/2020 flu season. Safety, as well as laboratory confirmed influenza incidence will be assessed, with results expected in the second half of 2020.

  • BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
    PR Newswire

    BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial

    JERUSALEM, Oct. 22, 2018 /PRNewswire/ --  BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of an €8 million disbursement from the European Investment Bank (EIB). The first two tranches totaling €12 million were received by BiondVax earlier this year.